³ë¹ÙƼ½ºÀÇ ÇÁ·Î¸·Å¸(Promacta, eltrombopag)°¡ FDA·Î ºÎÅÍ ÁßÁõ Àç»ýºÒ·®¼º ºóÇ÷¿¡ ´ëÇÑ 1Â÷ Ä¡·áÁ¦·Î ȹ±âÀûÀǾàÇ°(breakthrough therapy designation) ÁöÁ¤À» ¹Þ¾Ò´Ù.
4ÀÏ(ÇöÁö½Ã°¢) ·ÎÀÌÅÍ Åë½ÅÀº FDA À¥»çÀÌÆ®¸¦ Àοë, ÀÌ°°ÀÌ º¸µµÇß´Ù.
ÇÁ·Î¸·Å¸´Â °ñ¼ö°¡ ÃæºÐÇÑ ÀûÇ÷±¸, ¹éÇ÷±¸, Ç÷¼ÒÆÇÀ» »ý¼ºÇÏÁö ¸øÇÏ´Â Àç»ýºÒ·®¼º ºóÇ÷ À̶ó´Â µå¹® Ç÷¾×Áúȯ¿¡ ´ëÇÑ Ä¡·áÁ¦·Î, ¸é¿ª¾ïÁ¦¿ä¹ý°ú º´Çà»ç¿ëÇϴ ȹ±âÀû Ä¡·áÁ¦·Î ÁöÁ¤µÆ´Ù.
ÇÁ·Î¸·Å¸´Â ¸¸¼º ¸é¿ª¼º Ç÷¼ÒÆÇ °¨¼ÒÁõ(chronic immune thrombocytopenia) ¼ºÀΰú ¼Ò¾Æ ȯÀÚ¿Í ÁßÁõ Àç»ýºÒ·®¼º ºóÇ÷¿¡ ´ëÇØ 2Â÷ Ä¡·áÁ¦·Î ½ÂÀÎµÈ ¹Ù ÀÖ´Ù.